Dr Suldan Abdullahi

Dr Suldan Abdullahi Daignostic schemas, clinical pearls, infographics, upadates and insights regarding internal medicine.

๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” ๐€๐‡๐€/๐€๐’๐€ ๐ ๐ฎ๐ข๐๐ž๐ฅ๐ข๐ง๐ž๐ฌ ๐จ๐ง ๐€๐œ๐ฎ๐ญ๐ž ๐ˆ๐ฌ๐œ๐ก๐ž๐ฆ๐ข๐œ ๐’๐ญ๐ซ๐จ๐ค๐ž ๐š๐ซ๐ž ๐จ๐ฎ๐ญ!1๏ธโƒฃ ๐“๐ข๐ฆ๐ž ๐ฌ๐ญ๐ข๐ฅ๐ฅ ๐ž๐ช๐ฎ๐š๐ฅ๐ฌ ๐›๐ซ๐š๐ข๐ง โ€” but systems now matter as much as...
27/01/2026

๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” ๐€๐‡๐€/๐€๐’๐€ ๐ ๐ฎ๐ข๐๐ž๐ฅ๐ข๐ง๐ž๐ฌ ๐จ๐ง ๐€๐œ๐ฎ๐ญ๐ž ๐ˆ๐ฌ๐œ๐ก๐ž๐ฆ๐ข๐œ ๐’๐ญ๐ซ๐จ๐ค๐ž ๐š๐ซ๐ž ๐จ๐ฎ๐ญ!

1๏ธโƒฃ ๐“๐ข๐ฆ๐ž ๐ฌ๐ญ๐ข๐ฅ๐ฅ ๐ž๐ช๐ฎ๐š๐ฅ๐ฌ ๐›๐ซ๐š๐ข๐ง โ€” but systems now matter as much as speed

The 2026 guideline strongly emphasizes regional stroke systems of care, advocating integrated EMSโ€“hospital networks with measurable quality metrics and rapid transfer pathways, rather than isolated hospital-centric care .

2๏ธโƒฃ ๐Œ๐จ๐›๐ข๐ฅ๐ž ๐’๐ญ๐ซ๐จ๐ค๐ž ๐”๐ง๐ข๐ญ๐ฌ (๐Œ๐’๐”๐ฌ) ๐š๐ซ๐ž ๐ง๐จ ๐ฅ๐จ๐ง๐ ๐ž๐ซ ๐ž๐ฑ๐ฉ๐ž๐ซ๐ข๐ฆ๐ž๐ง๐ญ๐š๐ฅ โ€” they are recommended

Where available, MSUs are recommended over conventional EMS to enable ultra-early thrombolysis and improved functional outcomes, marking a major systems-level upgrade in stroke care .

3๏ธโƒฃ ๐ƒ๐ž๐ฌ๐ญ๐ข๐ง๐š๐ญ๐ข๐จ๐ง ๐ฆ๐š๐ญ๐ญ๐ž๐ซ๐ฌ: Not every stroke should go to the nearest hospital

For suspected LVO, transport decisions should consider direct routing to EVT-capable centers, unless robust and rapid interhospital transfer systems exist โ€” shifting from โ€œnearestโ€ to โ€œmost appropriateโ€ hospital logic .

4๏ธโƒฃ ๐“๐ž๐ง๐ž๐œ๐ญ๐ž๐ฉ๐ฅ๐š๐ฌ๐ž ๐ฌ๐ญ๐š๐ง๐๐ฌ ๐ž๐ช๐ฎ๐š๐ฅ ๐ญ๐จ ๐š๐ฅ๐ญ๐ž๐ฉ๐ฅ๐š๐ฌ๐ž ๐ข๐ง ๐ญ๐ก๐ž ๐Ÿ’.๐Ÿ“-๐ก๐จ๐ฎ๐ซ ๐ฐ๐ข๐ง๐๐จ๐ฐ

The guideline endorses either alteplase or tenecteplase for IV thrombolysis within 4.5 hours, based on multiple trials showing non-inferiority and practical advantages of tenecteplase (bolus dosing, logistics) .

5๏ธโƒฃ ๐“๐ซ๐ž๐š๐ญ ๐๐ข๐ฌ๐š๐›๐ฅ๐ข๐ง๐  ๐ฌ๐ญ๐ซ๐จ๐ค๐ž ๐ฎ๐ซ๐ ๐ž๐ง๐ญ๐ฅ๐ฒ โ€” ๐ข๐ซ๐ซ๐ž๐ฌ๐ฉ๐ž๐œ๐ญ๐ข๐ฏ๐ž ๐จ๐Ÿ ๐๐ˆ๐‡๐’๐’ ๐ฌ๐œ๐จ๐ซ๐ž

Patients with disabling deficits must receive thrombolysis even with low NIHSS, eliminating the misconception that โ€œlow score = no lysisโ€ .

6๏ธโƒฃ ๐„๐ฑ๐ญ๐ž๐ง๐๐ž๐ ๐ญ๐ก๐ซ๐จ๐ฆ๐›๐จ๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐ง๐จ๐ฐ ๐Ÿ๐ข๐ซ๐ฆ๐ฅ๐ฒ ๐ข๐ฆ๐š๐ ๐ž-๐ ๐ฎ๐ข๐๐ž๐

IV thrombolysis is reasonable up to 9 hours or wake-up stroke, provided advanced imaging demonstrates salvageable penumbra (DWI-FLAIR or perfusion mismatch) .

7๏ธโƒฃ ๐ƒ๐ฎ๐š๐ฅ ๐š๐ง๐ญ๐ข๐ฉ๐ฅ๐š๐ญ๐ž๐ฅ๐ž๐ญ๐ฌ, ๐ง๐จ๐ญ ๐ญ๐ก๐ซ๐จ๐ฆ๐›๐จ๐ฅ๐ฒ๐ฌ๐ข๐ฌ, ๐Ÿ๐จ๐ซ ๐ง๐จ๐ง-๐๐ข๐ฌ๐š๐›๐ฅ๐ข๐ง๐  ๐ฆ๐ข๐ง๐จ๐ซ ๐ฌ๐ญ๐ซ๐จ๐ค๐ž

For minor non-disabling stroke within 4.5 hours, trials failed to show thrombolysis benefit โ€” DAPT is preferred in this population .

8๏ธโƒฃ ๐„๐•๐“ ๐ง๐จ๐ฐ ๐›๐ž๐ง๐ž๐Ÿ๐ข๐ญ๐ฌ ๐ž๐ฏ๐ž๐ง โ€œ๐ฅ๐š๐ซ๐ ๐ž-๐œ๐จ๐ซ๐žโ€ ๐ฌ๐ญ๐ซ๐จ๐ค๐ž๐ฌ โ€” ๐ฌ๐ž๐ฅ๐ž๐œ๐ญ๐ž๐ ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ ๐จ๐ง๐ฅ๐ฒ

The 2026 guideline expands EVT eligibility to some patients with larger ischemic cores, provided imaging and clinical criteria are met โ€” a paradigm shift from previous exclusions .

9๏ธโƒฃ ๐๐š๐ฌ๐ข๐ฅ๐š๐ซ ๐š๐ซ๐ญ๐ž๐ซ๐ฒ ๐จ๐œ๐œ๐ฅ๐ฎ๐ฌ๐ข๐จ๐ง: ๐„๐•๐“ ๐ซ๐ž๐œ๐จ๐ฆ๐ฆ๐ž๐ง๐๐ž๐ ๐ฎ๐ฉ ๐ญ๐จ ๐Ÿ๐Ÿ’ ๐ก๐จ๐ฎ๐ซ๐ฌ

For basilar artery occlusion with NIHSS โ‰ฅ10 and PC-ASPECTS โ‰ฅ6, EVT is now strongly recommended within 24 hours โ€” a major advance in posterior circulation stroke care .

๐Ÿ”Ÿ ๐๐ž๐๐ข๐š๐ญ๐ซ๐ข๐œ ๐ฌ๐ญ๐ซ๐จ๐ค๐ž ๐ž๐ง๐ญ๐ž๐ซ๐ฌ ๐ข๐ง๐ญ๐ž๐ซ๐ฏ๐ž๐ง๐ญ๐ข๐จ๐ง๐š๐ฅ ๐ž๐ซ๐š

For the first time, pediatric AIS is addressed:
EVT is reasonable in select children โ‰ฅ6 years (and even younger in expert centers), and alteplase may be considered within 4.5 hours, though efficacy remains uncertain .

1๏ธโƒฃ1๏ธโƒฃ ๐ˆ๐ง๐ญ๐ž๐ง๐ฌ๐ข๐ฏ๐ž ๐ ๐ฅ๐ฎ๐œ๐จ๐ฌ๐ž ๐ฅ๐จ๐ฐ๐ž๐ซ๐ข๐ง๐  ๐ข๐ฌ ๐ก๐š๐ซ๐ฆ๐Ÿ๐ฎ๐ฅ โ€” ๐ง๐จ๐ญ ๐ก๐ž๐ฅ๐ฉ๐Ÿ๐ฎ๐ฅ

Targeting glucose aggressively to 80โ€“130 mg/dL increases hypoglycemia without improving outcomes. Avoid โ€œtightโ€ glucose control in AIS .

1๏ธโƒฃ2๏ธโƒฃ ๐€๐ ๐ ๐ซ๐ž๐ฌ๐ฌ๐ข๐ฏ๐ž ๐๐ ๐ฅ๐จ๐ฐ๐ž๐ซ๐ข๐ง๐  ๐š๐Ÿ๐ญ๐ž๐ซ ๐ซ๐ž๐ฉ๐ž๐ซ๐Ÿ๐ฎ๐ฌ๐ข๐จ๐ง ๐ฆ๐š๐ฒ ๐ฐ๐จ๐ซ๐ฌ๐ž๐ง ๐จ๐ฎ๐ญ๐œ๐จ๐ฆ๐ž๐ฌ

Intensive SBP reduction to

12/01/2026

๐Ÿ™‹โ€โ™‚๏ธ๐ˆ๐Ÿ ๐š ๐ง๐ž๐ฐ๐ฅ๐ฒ ๐๐ข๐š๐ ๐ง๐จ๐ฌ๐ž๐ ๐๐ข๐š๐›๐ž๐ญ๐ข๐œ ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ ๐œ๐จ๐ฆ๐ž๐ฌ ๐ญ๐จ ๐ฎ๐ฌ ๐ฐ๐ก๐š๐ญ ๐ข๐ง๐ฏ๐ž๐ฌ๐ญ๐ข๐ ๐š๐ญ๐ข๐จ๐ง๐ฌ ๐ฌ๐ก๐จ๐ฎ๐ฅ๐ ๐ฐ๐ž ๐š๐๐ฏ๐ข๐ฌ๐ž? โ“
:

For a newly diagnosed diabetes patient, the objective of baseline investigations is threefold: (๐Ÿ) ๐œ๐จ๐ง๐Ÿ๐ข๐ซ๐ฆ ๐š๐ง๐ ๐ฉ๐ก๐ž๐ง๐จ๐ญ๐ฒ๐ฉ๐ž ๐๐ข๐š๐›๐ž๐ญ๐ž๐ฌ, (๐Ÿ) ๐š๐ฌ๐ฌ๐ž๐ฌ๐ฌ ๐œ๐š๐ซ๐๐ข๐จ๐ฏ๐š๐ฌ๐œ๐ฎ๐ฅ๐š๐ซ ๐š๐ง๐ ๐ซ๐ž๐ง๐š๐ฅ ๐ซ๐ข๐ฌ๐ค, ๐š๐ง๐ (๐Ÿ‘) ๐๐ž๐ญ๐ž๐œ๐ญ ๐œ๐จ๐ฆ๐ฉ๐ฅ๐ข๐œ๐š๐ญ๐ข๐จ๐ง๐ฌ ๐š๐ฅ๐ซ๐ž๐š๐๐ฒ ๐ฉ๐ซ๐ž๐ฌ๐ž๐ง๐ญ ๐š๐ญ ๐๐ข๐š๐ ๐ง๐จ๐ฌ๐ข๐ฌ. The following represents a comprehensive, guideline-concordant initial evaluation suitable for routine clinical practice.

๐ŸŸฉ๐Ÿ. ๐†๐ฅ๐ฒ๐œ๐š๐ž๐ฆ๐ข๐œ ๐€๐ฌ๐ฌ๐ž๐ฌ๐ฌ๐ฆ๐ž๐ง๐ญ (๐ƒ๐ข๐š๐ ๐ง๐จ๐ฌ๐ข๐ฌ & ๐๐š๐ฌ๐ž๐ฅ๐ข๐ง๐ž ๐‚๐จ๐ง๐ญ๐ซ๐จ๐ฅ)

Fasting plasma glucose (FPG)

Post-prandial plasma glucose (PPG) or 2-hour OGTT (if diagnostic uncertainty)

HbA1c (baseline glycaemic burden)

Random plasma glucose (if symptomatic)

๐๐ฎ๐ซ๐ฉ๐จ๐ฌ๐ž: confirm diagnosis, assess chronic hyperglycaemia, and guide intensity of therapy.

๐ŸŸฉ๐Ÿ. ๐‘๐ž๐ง๐š๐ฅ ๐„๐ฏ๐š๐ฅ๐ฎ๐š๐ญ๐ข๐จ๐ง

Serum creatinine with eGFR

Urine albuminโ€“creatinine ratio (UACR) (spot urine)

Routine urine examination (protein, sediments, infection)

๐๐ฎ๐ซ๐ฉ๐จ๐ฌ๐ž: detect early diabetic kidney disease and stratify CV risk.

๐ŸŸฉ๐Ÿ‘. ๐‹๐ข๐ฉ๐ข๐ & ๐‚๐š๐ซ๐๐ข๐จ๐ฏ๐š๐ฌ๐œ๐ฎ๐ฅ๐š๐ซ ๐‘๐ข๐ฌ๐ค ๐๐ซ๐จ๐Ÿ๐ข๐ฅ๐ž

Fasting lipid profile

Total cholesterol

LDL-C

HDL-C

Triglycerides

Non-HDL cholesterol (derived)

Blood pressure measurement

Resting ECG (baseline) in adults, especially >40 years or with risk factors

๐๐ฎ๐ซ๐ฉ๐จ๐ฌ๐ž: atherosclerotic cardiovascular disease (ASCVD) risk stratification and statin decision.

๐ŸŸฉ๐Ÿ’. ๐‡๐ž๐ฉ๐š๐ญ๐ข๐œ & ๐Œ๐ž๐ญ๐š๐›๐จ๐ฅ๐ข๐œ ๐„๐ฏ๐š๐ฅ๐ฎ๐š๐ญ๐ข๐จ๐ง

Fib-4 Score

Liver function tests (ALT, AST, ALP, bilirubin)

Ultrasound abdomen (if obesity, metabolic syndrome, elevated ALT โ†’ screen for MASLD/MASH)

Serum uric acid (optional, cardiometabolic risk marker)

๐ŸŸฉ๐Ÿ“. ๐‡๐ž๐ฆ๐š๐ญ๐จ๐ฅ๐จ๐ ๐ข๐œ & ๐†๐ž๐ง๐ž๐ซ๐š๐ฅ ๐๐ข๐จ๐œ๐ก๐ž๐ฆ๐ข๐ฌ๐ญ๐ซ๐ฒ

Complete blood count (CBC)

Electrolytes (Naโบ, Kโบ, bicarbonate)

Serum calcium

Vitamin B12 (especially if metformin anticipated or long-term)

๐ŸŸฉ๐Ÿ”. ๐ƒ๐ข๐š๐›๐ž๐ญ๐ž๐ฌ ๐‚๐จ๐ฆ๐ฉ๐ฅ๐ข๐œ๐š๐ญ๐ข๐จ๐ง ๐’๐œ๐ซ๐ž๐ž๐ง๐ข๐ง๐  ๐š๐ญ ๐๐š๐ฌ๐ž๐ฅ๐ข๐ง๐ž

๐Ÿ”น๐€. ๐„๐ฒ๐ž

Dilated fundus examination / fundus photography (retinopathy may be present at diagnosis in T2D)

๐Ÿ”น๐. ๐Š๐ข๐๐ง๐ž๐ฒ

UACR + eGFR (as above)

๐Ÿ”น๐‚. ๐๐ž๐ฎ๐ซ๐จ๐ฉ๐š๐ญ๐ก๐ฒ / ๐…๐จ๐จ๐ญ

Comprehensive foot examination
(monofilament, vibration, pulses, deformities, callus, footwear assessment)

๐ŸŸฉ๐Ÿ•. ๐„๐ญ๐ข๐จ๐ฅ๐จ๐ ๐ข๐œ๐š๐ฅ / ๐๐ก๐ž๐ง๐จ๐ญ๐ฒ๐ฉ๐ข๐œ ๐“๐ž๐ฌ๐ญ๐ฌ (๐’๐ž๐ฅ๐ž๐œ๐ญ๐ข๐ฏ๐ž)

Indicated when presentation is atypical (young, lean, ketosis, rapid progression, insulin dependence):

๐Ÿ”น๐‚-๐ฉ๐ž๐ฉ๐ญ๐ข๐๐ž (fasting or stimulated)

๐Ÿ”น๐€๐ฎ๐ญ๐จ๐š๐ง๐ญ๐ข๐›๐จ๐๐ข๐ž๐ฌ: GAD-65, IA-2, ZnT8 (suspected LADA / type 1)

๐Ÿ”น๐Š๐ž๐ญ๐จ๐ง๐ž๐ฌ (urine or blood) if symptomatic or hyperglycaemia >300 mg/dL

๐ŸŸฉ๐Ÿ–. ๐ˆ๐ง๐Ÿ๐ž๐œ๐ญ๐ข๐จ๐ง & ๐๐ซ๐ž๐ฏ๐ž๐ง๐ญ๐ข๐ฏ๐ž ๐‡๐ž๐š๐ฅ๐ญ๐ก (๐š๐ฌ ๐š๐ฉ๐ฉ๐ซ๐จ๐ฉ๐ซ๐ข๐š๐ญ๐ž)

Hepatitis B, Hepatitis C, HIV (if risk factors)

Vaccination status review: influenza, pneumococcal, hepatitis B

Thyroid function tests (especially in T1D, women, or autoimmune background)

๐ŸŸฉ๐Ÿ—. ๐€๐๐๐ข๐ญ๐ข๐จ๐ง๐š๐ฅ ๐“๐ž๐ฌ๐ญ๐ฌ ๐ข๐ง ๐‡๐ข๐ ๐ก-๐‘๐ข๐ฌ๐ค ๐จ๐ซ ๐’๐ฉ๐ž๐œ๐ข๐š๐ฅ ๐’๐ข๐ญ๐ฎ๐š๐ญ๐ข๐จ๐ง๐ฌ

High-sensitivity CRP (CV risk refinement, optional)

Coronary risk assessment (stress test / CT-CAC) in selected high-risk asymptomatic individuals

Testosterone (men), PCOS evaluation (women) if clinically indicated

๐ŸŽฏ๐Œ๐ข๐ง๐ข๐ฆ๐ฎ๐ฆ ๐‚๐จ๐ซ๐ž ๐๐š๐ง๐ž๐ฅ (๐๐ซ๐š๐œ๐ญ๐ข๐œ๐š๐ฅ ๐‚๐ฅ๐ข๐ง๐ข๐œ ๐’๐ž๐ญ)๐ŸŽฏ

If resources are limited, the essential baseline panel should include:

FPG / PPG

HbA1c

Serum creatinine + eGFR

UACR

Fasting lipid profile

LFTs

CBC

Fundus examination

Comprehensive foot examination

Fib-4 Score

Follow-Up Frequency (Key Parameters)

HbA1c: every 3 months until controlled, then 6-monthly

UACR & eGFR: annually (6-monthly if abnormal)

Lipid profile: annually (or 6โ€“12 weeks after statin initiation)

Eye exam: annually

Foot exam: every visit / at least annually

11/01/2026

๐Ÿ“Œ waxad halkan si sahlan uga heli kartaa dhamaan guidelines asaaska ah (ADA, KDIGO, ACC/AHA, ESC, etc.) in one place โ€” with quick summaries and point-of-care tools.

๐Ÿ”— https://www.guidelinecentral.com/

11/01/2026
10/01/2026

๐๐ซ๐š๐œ๐ญ๐ข๐œ๐š๐ฅ ๐œ๐ฅ๐ข๐ง๐ข๐œ๐š๐ฅ ๐ฉ๐จ๐ข๐ง๐ญ๐ž๐ซ๐ฌ ๐ญ๐จ ๐๐ข๐Ÿ๐Ÿ๐ž๐ซ๐ž๐ง๐ญ๐ข๐š๐ญ๐ž ๐ƒ๐ข๐š๐›๐ž๐ญ๐ข๐œ ๐Š๐ข๐๐ง๐ž๐ฒ ๐ƒ๐ข๐ฌ๐ž๐š๐ฌ๐ž (๐ƒ๐Š๐ƒ) ๐Ÿ๐ซ๐จ๐ฆ ๐๐จ๐ง-๐ƒ๐ข๐š๐›๐ž๐ญ๐ข๐œ ๐Š๐ข๐๐ง๐ž๐ฒ ๐ƒ๐ข๐ฌ๐ž๐š๐ฌ๐ž (๐๐ƒ๐Š๐ƒ)

โœณ๏ธ ๐…๐ž๐š๐ญ๐ฎ๐ซ๐ž๐ฌ ๐’๐ฎ๐ ๐ ๐ž๐ฌ๐ญ๐ข๐ง๐  ๐“๐ฒ๐ฉ๐ข๐œ๐š๐ฅ ๐ƒ๐Š๐ƒ

๐Ÿ”นLong duration of diabetes
Usually >10 years in type 1 and >5โ€“10 years in type 2 diabetes.

๐Ÿ”นPresence of diabetic retinopathy
Strongly correlates with DKD; absence raises suspicion of NDKD.

๐Ÿ”นGradual onset of albuminuria
Progression: normoalbuminuria โ†’ microalbuminuria โ†’ overt proteinuria.

๐Ÿ”นSlow, predictable decline in eGFR
Progressive, over years rather than sudden deterioration.

๐Ÿ”นBland urinary sediment
No hematuria, red cell casts, or active sediment.

๐Ÿ”นHypertension and other microvascular complications
Neuropathy, retinopathy, and autonomic dysfunction often coexist.

๐Ÿ”นSymmetric kidney size on imaging
No marked asymmetry or structural abnormalities.

โœณ๏ธ๐‘๐ž๐ ๐…๐ฅ๐š๐ ๐ฌ ๐’๐ฎ๐ ๐ ๐ž๐ฌ๐ญ๐ข๐ง๐  ๐๐ƒ๐Š๐ƒ

๐Ÿ”ธShort diabetes duration
Renal disease appearing within

25/12/2025

Ten rules for the doctors

1. Be truthful.
Practice medicine the way you would want it practiced on you. Integrity in thought, speech, and action is non-negotiable.

2. Stay organized.
Your cognitive bandwidth is finite. Use systems (calendars, lists, routines) to reduce chaos and prevent avoidable errors.

3. Learn from mistakes.
You will err. Analyze failures honestly, correct course, and do not repeat them. Reflection is a professional obligation.

4. Ask.
Ignorance concealed is dangerous. Seek input from seniors, peers, nurses, and allied staff early and without embarrassment.

5. Communicate clearly.
Medicine fails when communication fails. Be precise, listen actively, avoid jargon, and confirm understanding.

6. Listen to patients.
Symptoms, fears, and values are data. Attention is not optional; it is diagnostic and therapeutic.

7. Stay sane.
You will encounter suffering, injustice, and death. Remain lucid and mentally intact. Protect time for recovery, burnout helps no one.

8. Stay curious.
Clinical competence decays without inquiry. Read, question, and adapt as evidence evolves.

9. Stand up.
Have principles. Authority does not equal correctness. Advocate for patients and for sound medicine, even when uncomfortable.

10. Be sincere.
Remember why you entered medicine. Let purpose, not convenience or fear, guide your conduct.

"A good doctor in a privileged or sh*tty hospital is still a good doctor" taken from my good

20/12/2025

1. ๐’๐“๐€๐“๐ˆ๐๐’: ๐“๐ก๐ž ๐’๐ข๐ฅ๐ž๐ง๐ญ ๐‚๐š๐ซ๐๐ข๐จ๐ฉ๐ซ๐จ๐ญ๐ž๐œ๐ญ๐จ๐ซ๐ฌ

A deep dive into how statins save lives โ€” who needs them, how to choose, how to monitor, and what not to fear.

Letโ€™s break myths, simplify guidelines & apply it to the Indian setting๐Ÿ‘‡

๐Ÿง  ๐Ÿ. ๐–๐ก๐š๐ญ ๐š๐ซ๐ž ๐’๐ญ๐š๐ญ๐ข๐ง๐ฌ?

Statins = HMG-CoA reductase inhibitors โ†’ block hepatic cholesterol synthesis โ†’ โ†“LDL-C & โ†‘LDL receptor activity.

Theyโ€™re the cornerstone for 1ry & 2ry prevention of ASCVD (heart attack, stroke, PAD).

๐Ÿ‘: ๐‡๐จ๐ฐ ๐ฌ๐ญ๐ซ๐จ๐ง๐  ๐ข๐ฌ ๐ฒ๐จ๐ฎ๐ซ ๐ฌ๐ญ๐š๐ญ๐ข๐ง?

๐Ÿ’ช High-intensity (โ†“LDL โ‰ฅ50%) โ†’ Atorvas 40โ€“80 mg / Rosuvas 20โ€“40 mg

โš–๏ธ Moderate-intensity (โ†“LDL 30โ€“49%) โ†’ Atorvas 10โ€“20 mg / Rosuvas 5โ€“10 mg / Simvas 20โ€“40 mg

๐Ÿ’ค Low-intensity (โ†“LDL

๐Ÿšจ Diabetes Diagnosis in 4 SIMPLE Steps! ๐ŸฉธStruggling to spot diabetes early? This infographic breaks down the EXACT crite...
16/12/2025

๐Ÿšจ Diabetes Diagnosis in 4 SIMPLE Steps! ๐Ÿฉธ

Struggling to spot diabetes early? This infographic breaks down the EXACT criteria:

โœ… HbA1c โ‰ฅ6.5% (NGSP-certified)
โœ… Fasting Plasma Glucose โ‰ฅ126 mg/dL (8hr fast)
โœ… 2h PG โ‰ฅ200 mg/dL (OGTT)
โœ… Random PG โ‰ฅ200 mg/dL (with classic symptoms)

2 abnormal tests needed if no symptoms!
Save & Share to spread awareness!

๐Ÿ’Š Empiric antibiotics donโ€™t need guesswork. They need structure.A simple 2025-ready approach:โœ” Treat only when bacterial...
14/12/2025

๐Ÿ’Š Empiric antibiotics donโ€™t need guesswork. They need structure.

A simple 2025-ready approach:
โœ” Treat only when bacterial infection is likely
โœ” Start smart for UTI, CAP, cellulitis
โœ” Skip antibiotics when they wonโ€™t help
โœ” Adjust for kidneys โ€” donโ€™t harm while helping
โœ” Reassess at 48โ€“72h and de-escalate

Good antibiotics save lives.
Unnecessary ones create resistance.

Normal blood pressure does not rule out sepsis.Lactate โ‰ฅ2 mmol/L, delayed vasopressors, fluid overload, and missed sourc...
14/12/2025

Normal blood pressure does not rule out sepsis.

Lactate โ‰ฅ2 mmol/L, delayed vasopressors, fluid overload, and missed sources are where outcomes are decided.

A practical 2025 guide to sepsis recognition and early management.

Address

Cairo

Website

https://t.me/sulmedd

Alerts

Be the first to know and let us send you an email when Dr Suldan Abdullahi posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram